Centers, HSCD

Medicine & Life Sciences

1. 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one 26%
2. Acquired Immunodeficiency Syndrome 10%
3. Acute Myeloid Leukemia 13%
4. Adenocarcinoma 8%
5. Adenoma 22%
6. Adrenal Cortex Hormones 11%
7. Antibodies 9%
8. Apoptosis 10%
9. Asthma 100%
10. Autologous Transplantation 8%
11. Biomarkers 8%
12. Biopsy 10%
13. Bone and Bones 9%
14. Bone Marrow 15%
15. Bone Marrow Transplantation 17%
16. Breast Neoplasms 51%
17. Busulfan 9%
18. Carcinoma 22%
19. Cell Line 21%
20. Cell Transplantation 9%
21. Chemoprevention 10%
22. Child 36%
23. Cisplatin 20%
24. Clinical Trials 10%
25. Colonic Neoplasms 10%
26. Colorectal Neoplasms 11%
27. Combination Drug Therapy 8%
28. Confidence Intervals 15%
29. Contrast Media 9%
30. Cyclophosphamide 29%
31. Denosumab 8%
32. Disease-Free Survival 9%
33. DNA 11%
34. Doxorubicin 29%
35. Drug Therapy 29%
36. Etoposide 15%
37. Genes 21%
38. Genome-Wide Association Study 11%
39. Growth 10%
40. Hypersensitivity 13%
41. Immunoglobulin E 20%
42. Immunotherapy 10%
43. In Vitro Techniques 17%
44. Incidence 9%
45. Integrins 14%
46. Interferons 11%
47. Interleukin-2 9%
48. kalinin 8%
49. Kidney 8%
50. Leukemia 14%
51. Liposomes 8%
52. Liver 9%
53. Lung 19%
54. Lymphocytes 13%
55. Matrix Metalloproteinase 7 10%
56. Melanoma 37%
57. Microbubbles 10%
58. Mitomycin 10%
59. Multiple Myeloma 9%
60. Mutation 8%
61. Neoplasm Metastasis 16%
62. Neoplasms 59%
63. Non-Small Cell Lung Carcinoma 23%
64. Odds Ratio 10%
65. Paclitaxel 10%
66. Parturition 14%
67. Pediatrics 10%
68. Pharmaceutical Preparations 17%
69. Pharmacokinetics 14%
70. Phenotype 15%
71. Placebos 17%
72. Population 12%
73. Progression-Free Survival 11%
74. promatrilysin 10%
75. Prostate 32%
76. Prostate-Specific Antigen 14%
77. Prostatic Intraepithelial Neoplasia 9%
78. Prostatic Neoplasms 35%
79. Proteins 11%
80. Radiotherapy 12%
81. Randomized Controlled Trials 8%
82. Recurrence 15%
83. Respiratory Sounds 33%
84. Respiratory System 9%
85. Sarcoma 11%
86. Selenium 12%
87. Serum 20%
88. Sexual and Gender Minorities 8%
89. Single Nucleotide Polymorphism 14%
90. Skin 15%
91. Skin Tests 9%
92. Small Cell Lung Carcinoma 19%
93. Smoking 11%
94. Survival 29%
95. T-Lymphocytes 8%
96. Tamoxifen 8%
97. Tea 9%
98. Therapeutics 29%
99. Transplants 9%
100. Vincristine 10%